Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Emory University
Eli Lilly and Company
Seagen Inc.
Montefiore Medical Center
Taiho Oncology, Inc.
Alliance for Clinical Trials in Oncology
Mayo Clinic
University Health Network, Toronto
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Barts & The London NHS Trust
University of Southern California
Eli Lilly and Company
AHS Cancer Control Alberta
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
University Hospital, Geneva
University of Nebraska
HonorHealth Research Institute
University of Texas Southwestern Medical Center
Emory University
CanBas Co. Ltd.
Medical College of Wisconsin
Eastern Cooperative Oncology Group
HonorHealth Research Institute
Roswell Park Cancer Institute
Bayer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UNICANCER
University of California, San Diego
Piedmont Cancer Institute
Medical College of Wisconsin
Pancreatic Cancer Research Team
Critical Outcome Technologies Inc.
University of Pisa
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
IRCCS San Raffaele
IRCCS San Raffaele
Alliance for Clinical Trials in Oncology
University of Michigan Rogel Cancer Center
Emory University
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
IRCCS San Raffaele
CONKO-Studiengruppe